Vicara Therapeutics achieves patient enrollment for FORTIFI-HN01 clinical trial and plans interim survival analysis
BCAX Bicara Therapeutics Inc
$9.98 +15.38%
View chart & analysis → - 1Interim CEO Ryan Colhep announced that the FORTIFI-HN01 clinical study has achieved sufficient patient enrollment to perform an interim analysis.
- 2Vicara Therapeutics is planning an interim overall survival analysis.
- 3CFO Jennifer Larson stated that the company holds cash assets sufficient to sustain operations through the first half of 2029.
So what's the key point?
Vicara Therapeutics has finished recruiting the patients needed for its clinical study. The company is now planning an interim survival analysis and has enough money to last until the first half of 2029.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.